Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Axa S.A.

Axa S.A. grew its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 52.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 270,778 shares of the company’s stock after buying an additional 92,616 shares during the period. Axa S.A. owned 0.56% of Cabaletta Bio worth $2,025,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. California State Teachers Retirement System grew its position in Cabaletta Bio by 6.0% in the first quarter. California State Teachers Retirement System now owns 30,428 shares of the company’s stock worth $519,000 after acquiring an additional 1,711 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Cabaletta Bio by 65.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company’s stock valued at $140,000 after purchasing an additional 3,244 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in shares of Cabaletta Bio by 7.7% during the 2nd quarter. AlphaCentric Advisors LLC now owns 70,000 shares of the company’s stock worth $524,000 after purchasing an additional 5,000 shares during the period. TD Asset Management Inc increased its position in shares of Cabaletta Bio by 5.5% during the 2nd quarter. TD Asset Management Inc now owns 134,030 shares of the company’s stock worth $1,003,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Swiss National Bank raised its holdings in Cabaletta Bio by 16.1% in the 1st quarter. Swiss National Bank now owns 59,200 shares of the company’s stock valued at $1,010,000 after buying an additional 8,200 shares during the period.

Cabaletta Bio Trading Up 10.8 %

NASDAQ:CABA opened at $4.72 on Tuesday. Cabaletta Bio, Inc. has a 12-month low of $3.47 and a 12-month high of $26.35. The firm has a market cap of $227.87 million, a PE ratio of -2.76 and a beta of 2.40. The stock has a fifty day moving average price of $5.24 and a 200 day moving average price of $9.63.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). Equities analysts forecast that Cabaletta Bio, Inc. will post -2.21 EPS for the current year.

Wall Street Analyst Weigh In

CABA has been the subject of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 target price on shares of Cabaletta Bio in a research note on Monday, June 17th. Evercore ISI dropped their target price on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Cabaletta Bio in a research note on Friday, June 21st. Wells Fargo & Company dropped their price objective on Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a research note on Tuesday, September 17th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Cabaletta Bio has a consensus rating of “Buy” and a consensus price target of $30.11.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.